Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

Inclusion Criteria:

- Age ≥18 years

- Stage 1-4 invasive breast cancer that is histologically confirmed at MSKCC

- Status post mastectomy with axillary exploration (sentinel node biopsy and/or axillary
lymph node dissection) to receive PMRT

- ECOG Performance Status of 0 or 1

Exclusion Criteria:

- Male

- Patients with clinical evidence of gross disease

- Patients who are pregnant or breastfeeding

- Prior radiation therapy to the ipsilateral chest wall or thorax

- Patients requiring a chest wall boost

- Concurrent chemotherapy (biologic agents are allowed)

- Psychiatric illness that would prevent the patient from giving informed consent

- Inability or unwillingness to comply with skin care instructions and follow-up

- Allergy to either Eucerin or MF

- Residual grade >1 skin toxicity, cellulitis, or incompletely healed wound(s) at
intended site of study drug application at the time of the start of RT

- Medical condition such as uncontrolled infection (including HIV), uncontrolled
diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other
collagen vascular diseases)

- Treatment with palliative or pre-operative radiation